Ribupatide

DRUG5 trials

Sponsors

Kailera

Conditions

End Stage Renal DiseaseObesityObesity With DiabetesOverweightOverweight With DiabetesRenal Impairment

Phase 1

A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

Not yet recruitingNCT07793929

KaileraEnd Stage Renal Disease, Obesity, Overweight +1

Start: 2026-09-08End: 2028-02-08Target: 32Updated: 2026-09-03

Phase 2

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Active, not recruitingNCT07458269

Start: 2026-03-04End: 2027-06-01Updated: 2026-07-15

Phase 3

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

RecruitingNCT07284875

KaileraObesity, Overweight

Start: 2025-12-18End: 2028-03-01Target: 2340Updated: 2026-09-03

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

RecruitingNCT07284979

Start: 2025-12-30End: 2028-04-01Target: 1200Updated: 2026-09-01

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

RecruitingNCT07284901

KaileraObesity With Diabetes, Overweight With Diabetes

Start: 2026-01-12End: 2028-04-24Target: 1156Updated: 2026-09-03